Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.210
-0.060 (-2.64%)
Feb 21, 2025, 4:00 PM EST - Market closed
Nuvation Bio Employees
Nuvation Bio had 51 employees as of December 31, 2023. The number of employees decreased by 2 or -3.77% compared to the previous year.
Employees
51
Change (1Y)
-2
Growth (1Y)
-3.77%
Revenue / Employee
$42,392
Profits / Employee
-$10,436,882
Market Cap
743.81M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 51 | -2 | -3.77% |
Dec 31, 2022 | 53 | -11 | -17.19% |
Dec 31, 2021 | 64 | 28 | 77.78% |
Dec 31, 2020 | 36 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
NUVB News
- 4 days ago - Kuehn Law Encourages Investors of Nuvation Bio Inc. to Contact Law Firm - PRNewsWire
- 8 days ago - Nuvation Bio: Pending Approval Shot In ROSL+ NSCLS Looks A Major Upside Catalyst - Seeking Alpha
- 19 days ago - Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer - Business Wire
- 6 weeks ago - Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 weeks ago - Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer - Business Wire
- 7 weeks ago - Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration - PRNewsWire
- 2 months ago - U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio's New Drug Application for Taletrectinib for the Treatment of Advanced ROS1-positive Non-Small Cell Lung Cancer - Business Wire
- 2 months ago - Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration - PRNewsWire